Cardarine and MK-2866 Interaction

Compatible
Researched 90% confidence

Cardarine and MK-2866 have a compatible interaction with 90% confidence. Cardarine (GW-501516) is a PPAR-delta agonist that enhances fatty acid oxidation and endurance without interacting with the androgen receptor. It does not contribute to HPTA suppression, making it a common addition to MK-2866 cycles targeting body recomposition or cutting goals. Both compounds affect the liver, so monitoring these systems is recommended.

Compound Profiles

Cardarine

PPAR-delta Agonist | Endurance & Fat Metabolism

Cardarine acts as a potent and highly selective agonist of PPAR-delta, a nuclear hormone receptor expressed in skeletal muscle, liver, adipose tissue, and the gastrointestinal tract. Upon binding to PPAR-delta, Cardarine triggers a conformational change that promotes heterodimerization with retinoid X receptor (RXR), and the resulting complex binds to PPAR response elements (PPREs) in the promoter regions of target genes.

Half-life: ~16-24 hours Typical dose: 10-20 mg/day sarm, metabolic
ppar delta carcinogenic riskhpta suppressiveinsulin disruptinglipid disrupting
View full profile

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

Combined Organ Load

Liver
moderate
Gonads
moderate
Heart
low
Pancreas
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (Cardarine, MK-2866). Monitor accordingly.
2x 2 HPTA-suppressive compounds (Cardarine, MK-2866). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (Cardarine, MK-2866). Get lipid panel mid-cycle — consider adding lipid support.

Frequently Asked Questions

Can I take Cardarine with MK-2866?

Yes, Cardarine and MK-2866 can generally be taken together. Cardarine (GW-501516) is a PPAR-delta agonist that enhances fatty acid oxidation and endurance without interacting with the androgen receptor. It does not contribute to HPTA suppression, making it a common addition to MK-2866 cycles targeting body recomposition or cutting goals.

Is Cardarine and MK-2866 safe together?

Based on documented research, this combination is considered compatible. However, shared safety flags include: carcinogenic risk, hpta suppressive, lipid disrupting. Monitor accordingly.

What are the interactions between Cardarine and MK-2866?

Cardarine (GW-501516) is a PPAR-delta agonist that enhances fatty acid oxidation and endurance without interacting with the androgen receptor. It does not contribute to HPTA suppression, making it a common addition to MK-2866 cycles targeting body recomposition or cutting goals. This assessment has 90% confidence and is based on documented research data.

How should I time Cardarine and MK-2866?

Cardarine has a half-life of ~16-24 hours and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Cardarine vs MK-2866

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.